Clinical trials are medical research studies in which people participate as volunteers. They help researchers learn more about diseases and conditions and develop new treatments and medications. Learn more about clinical trials here.
Below are clinical trials currently recruiting juvenile myositis patients. JDM and JPM patients of various ages may be eligible for these trials. For detailed information about a particular trial, please contact the study team directly.
If you have any questions, please contact Cure JM’s Family and Clinician Education Manager at James.Tealy@curejm.org.
Cabaletta Bio CAR-T trial
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy
Cabaletta Bio RESET-Myositis Trial:
RESET-Myositis is a phase 1/2 clinical trial being conducted to evaluate the effects of an investigational CAR-T treatment, called CABA-201, in myositis.
Who is eligible for this clinical trial?
You or someone you know may be eligible to participate if you:
- Have been diagnosed with myositis or juvenile myositis, including juvenile dermatomyositis and juvenile polymyositis patients
- Are 6+ years of age for the Juvenile Cohort (Chicago, IL – Comer Children’s Hospital)
- Are 18+ years of age for the Adult Cohort (all listed sites below)
- Have active disease
- Additional requirements will apply, and only a study doctor can determine eligibility to participate in the study.
- Recruitment is currently open at the following locations below. For a full list of study sites click here.
- Orange County, CA
- Jacksonville, FL – Mayo Clinic
- Chicago, IL – Northwestern Memorial Hospital
- Chicago, IL – University of Chicago Medical Center
- Kansas City, KS – University of Kansas Medical Center
- Rochester, MN – Mayo Clinic
- Portland, OR – Oregon Health & Science University
- Nashville, TN – Vanderbilt University Medical Center
- Houston, TX – Houston Methodist Hospital
- Houston, TX – University of Texas MD Anderson Medical Center
Next Steps If You Are Interested:
- Speak with Your Doctor: Discuss this trial with your healthcare provider to determine if it’s a good fit.
- Contact the Study Team: Reach out to the research team for detailed information, including eligibility requirements, locations, and potential risks and benefits. Please email clinicaltrials@cabalettabio.com and the study site closest to you. Find the list of study sites here.
- Ask Questions: It’s important to fully understand the trial’s process, expectations, and how participation might affect your care.
Cabaletta Bio RESET-Myositis Trial FAQs can be reviewed here.
Phone: +1-267-759-3100
Century Therapeutics CAR-NK trial
JDM and JPM patients age 17+ are eligible to participate; please contact one of the sites listed here. This study is called the CALiPSO-1 Study. It is a study of CNTY-101, which is a CD19-targeted CAR-NK Cell Product. This is being tested in participants with refractory B Cell-mediated autoimmune diseases like JDM and JPM.
Who is eligible for this clinical trial?
You or someone you know may be eligible for this clinical trial. For a full list of participation criteria, click here.
Recruitment is currently open at the following locations below. For a full list of study sites, click here.
- Los Angeles, CA – Keck School of Medicine University of Southern California
- Chicago, IL – Lurie Children’s; Northwestern Medicine – Northwestern Medical Group
- Houston, TX – Texas Children’s Hospital
- Salt Lake City, UT – Primary Children’s Hospital
CALiPSO-1 Study Sites Not Yet Recruiting:
- Sacramento, CA – UC Davis
Note: You may see the term “IIM” listed on the trial site. In medicine, IIM stands for Idiopathic Inflammatory Myopathies. IIM refers to the group of rare diseases is characterized by chronic muscle inflammation and includes conditions like JDM, JPM, and others.
If you have any questions related to this trial, please contact Shannon Malloy at Shannon.Malloy@curejm.org.
Opportunity to Participate in the JASMINE Clinical Trial for Polymyositis & Dermatomyositis
A new clinical trial, JASMINE, is currently enrolling participants to evaluate the efficacy and safety of anifrolumab when added to standard care.
Who Is Eligible?
- Patients age 18+ who were diagnosed with juvenile myositis, polymyositis,dermatomyositis
- Other qualifications may apply, contact the study for more details
Trial Details
- Investigating anifrolumab (a subcutaneous injection) in combination with standard treatments
- Conducted at multiple sites across the U.S.
How to Learn More
Call: 1-877-240-9479
Email: information.center@astrazeneca.com
View trial sites & eligibility: JASMINE Clinical Trial on ClinicalTrials.gov